Carcinoma;Endocrine, Neuroendocrine Tumors
Conditions
Brief summary
Multicenter retrospective longitudinal analytical study of patients with neuroendocrine tumors.
Interventions
None listed
Sponsors
Latin American Cooperative Oncology Group
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 18 years or older and with histologically confirmed neuroendocrine tumors; * Metastatic or inoperable disease; * Patients with clinical information about the therapies received, including exclusive palliative care.
Exclusion criteria
* Lack of data on survival outcomes and/or details on treatments received.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | 2022 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Response rate per RECIST 1.1; | 2022 | — |
| Progression-free survival by RECIST 1.1 from D1 of each treatment; | 2022 | — |
| Symptom control time | 2022 | Improvement of symptoms and/or stabilization of radiological disease in non-functioning ENT, at the physician's discretion |
| Incidence of complications of the disease and/or treatments, defined by adverse events | 2022 | — |
Countries
Argentina, Brazil, Mexico, Peru
Contacts
PRINCIPAL_INVESTIGATORRachel Riechelmann
AC Camargo Cancer Center
Outcome results
None listed